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Abstract
Background: To compare image quality and diagnostic performance of Gadoteridol-enhanced MR angiography
(MRA) with Gadobutrol-enhanced MRA in the evaluation of carotid artery stenosis.
Methods: MRA was performed in 30 patients with carotid stenosis diagnosed at DUS. Patients were randomly
assigned to group A (Gadobutrol-enhanced MRA) or group B (Gadoteridol-enhanced MRA). All examinations were
performed with a 3T MR system. Image quality was assessed qualitatively by a 3-grade scale and quantitatively with
SNR measurements. Diagnostic performance in the assessment of stenosis, plaque length and morphology was
evaluated in the two MRA groups by accuracy calculation and RoC curves analysis using CTA as reference standard.
Statistically significant differences in SNR and quality scale were evaluated by the Independent-Samples T Test and
Mann–Whitney test, while the Z-statistics was used to compare diagnostic accuracy in the two groups.
Results: Image quality was graded adequate to excellent for both GBCAs, without significant differences (p = 0.165).
SNR values were not significantly different in group B (Gadoteridol-enhanced MRA) as compared to group A
(Gadobutrol-enhanced MRA) (89.32 ± 70.4 vs 81.09 ± 28.38; p = 0.635). Diagnostic accuracy was 94 % for the
evaluation of stenosis degree and 94 % for the identification of ulcerated plaques in group A, while it was 93 %
for the evaluation of stenosis degree and 76 % for the identification of ulcerated plaques in group B, without
statistically significant differences (p = 0.936).
Conclusion: No significant difference in terms of image quality and diagnostic accuracy was observed between
Gadoteridol-enhanced MRA and Gadobutrol-enhanced MRA in patients undergoing evaluation of carotid stenosis.
Background
Ischemic stroke is estimated to be responsible for 10 % of
all deaths worldwide. It is the second cause of mortality in
western countries and the leading cause of mortality in
China and Japan [1]. Atherosclerotic disease of the extra-
cranial internal carotid arteries can be recognized as the
cause of stroke at least in 25–30 % of patients [1].
Over the last decade, CT-angiography (CTA) and MR-
angiography (MRA) have attained a cardinal role in the
imaging of carotid arteries thanks to their increasing
diagnostic reliability [2–5]. Since the introduction of
contrast-enhanced MRA, several gadolinium-based con-
trast agents (GBCA) have been tested and implemented
in clinical practice [6–9], ranging from standard inter-
stitial molecules to high relaxivity and blood-pool agents
[4, 9, 10]. Currently, however, there is no common con-
sensus as to which contrast medium should be used for
MRA. Gadoteridol (ProHance®, Bracco) is a macrocyclic
gadolinium chelate with a recognized low-rate of adverse
side effects. Moreover, it is the sole agent approved for
high-dose administration (0.3 mmol/kg) due in part to its
high stability and thus lower potential for toxicity from
long-term heavy metal deposition [11, 12]. Despite the
inherent safety of Gadoteridol, only a few studies have
evaluated the performance of this contrast medium in
MRA [13–16].
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The purpose of this study was to prospectively com-
pare the image quality and diagnostic performance of
Gadoteridol enhanced MRA with that of Gadobutrol
(Gadovist®, Bayer) enhanced MRA in the evaluation of
carotid artery stenosis, using CTA as reference standard.
Methods
Patient population
Between November 2013 and February 2015, 30 consecu-
tive patients (19 men, 11 women; mean age 71.96 ± 7.6,
age range 51–76 years) with confirmed internal carotid
artery (ICA) stenosis were enrolled. Institutional Review
Board (IRB) (Sapienza - University of Rome) and patient
informed consent were obtained. For a patient to be
included confirmation of at least one of the following
criteria was needed:
1. Doppler-ultrasonography (DUS) showing a
hemodynamically significant stenosis of the internal
carotid artery (PSV 125 cm/s);
2. Ultrasound examination showing a stenosis of >30 %
according to NASCET criteria [17];
3. Ultrasound examination showing a heterogeneous
plaque, irregular surface, intra-plaque hemorrhage
or ulceration;
Patients with a general contraindication to MRA/CTA
examination and/or with a known allergy to contrast
agents and/or laboratory signs of renal failure were
excluded from the study.
Imaging technique
Patients were randomly assigned to group A or B, under-
going MRA after the administration of 0.1 mmol/kg
Gadobutrol (0.1 mL/kg) and 0.1 mmol/kg Gadoteridol
(0.2 ml/kg), respectively; randomization was performed
according to a 2:1 ratio with 2/3 of patients undergoing
Gadoteridol enhanced MRA.
All examinations were performed on a 3T system
(Discovery MR750, GE Healthcare, Milwaukee-WIS, USA;
with peak gradient strength 50 mT/m, peak slew rate
200 mT/m/ms, HD Neurovascular Array configuration
8-channel, 12-element) with the same technical parame-
ters (T1-weighted 3D SPGRE sequence, TR 4.8 ms, TE
1.8, FA 25°, thickness 0.8 mm, matrix 418 × 418) in both
groups. A contrast agent bolus was administered with
an automatic injector at a rate of 1 ml/s through an
18-gauge cannula placed in the antecubital vein of the
right arm, followed by 15 ml of saline solution. The
optimal delay between injection and MRA acquisition
was visually evaluated by the bolus tracking technique.
CTA was performed on a 128-MDCT scanner (Somatom
Definition, Siemens Medical System Erlangen, Germany)
using a dual-energy protocol (80 kV and 140 kV, 200 mAs,
pitch 0.8, slice-thickness 1 mm, recon increment 0.9 mm,
matrix 512×512). The optimal delay between contrast
administration and scan was evaluated with the bolus-
tracking technique, with a region of interest (ROI) placed
at the level of the aortic arch and automatic scan trigger-
ing with enhancement threshold set at 150 HU. The
acquisition was performed after administration of 50 ml of
nonionic iodinated contrast material (Iomeprol 400 mgI/
ml, Iomeron 400, Bracco, Milan, Italy), followed by the
injection of 30 ml of saline solution at a rate of 4 ml/s with
the use of a dual-head injector.
Image analysis
An independent observer (B.S. with 8 years of experience
in cardiovascular imaging), blinded to the contrast agent
used, assessed the quality of all MRA datasets using a 3-
point scale (poor: inhomogeneous vessel enhancement,
poor intraluminal signal and wall delineation; adequate:
homogenous vessel enhancement, sufficient intraluminal
signal and wall delineation, motion artifacts that did not
impair measurements; excellent: homogenous vessel en-
hancement, high intraluminal signal, precise wall delinea-
tion, no motion artifacts). Quantitative measurements of
signal-to-noise ratio (SNR; signal Intensity in the vessel/
Standard Deviation (SD) outside the body) were also
performed on each dataset by the same observer. More in
detail, in each case a vessel ROI was placed in the terminal
common carotid artery just proximal to carotid bifur-
cation, whereas the background-ROIs were obtained for 3
different images, in ghosts-free areas. Two readers (F.Z.
with 9 years’ experience and M.A. with 13 years’ experi-
ence in MRA of the carotid arteries), who were blinded to
the contrast agent used, independently evaluated MRA
datasets for the presence and degree of steno-occlusive
disease (according to NASCET criteria) and plaque char-
acteristics. All image sets were presented in random order
to each reader. An independent reader (I.C. with 18 years’
experience in cardiovascular imaging) evaluated the sten-
osis degree and plaque characteristics on CTA images.
Statistical analysis
Statistical analysis was performed using dedicated software
(STATA SE 12 for Macintosh; Stata Corporation; College
Station, Texas, USA). The normality of each continuous
variable group was tested using the Kolmogorov-Smirnov
Z test. Continuous data are described as the mean
value ± Standard Deviation [95 % confidence interval]
or [minimum – maximum] as appropriate; categorical
data are expressed as number (percentage). The Mann–
Whitney test was applied to determine significant differ-
ences in image quality between the two contrast agents.
CTA was used as the reference standard for ROC curve
analysis and to calculate sensitivity, specificity, positive pre-
dictive value (PPV), negative predictive value (NPV) and
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accuracy for stenosis degree and plaque morphology
(i.e. plaque ulceration or surface irregularity); a stenosis of
70 % was used as threshold level for stenosis degree. Areas
under the curve (AUC) were compared using the Z-
statistic to determine differences in diagnostic performance
between the two contrast agents [18]. Pearson’s cor-
relation coefficient was used to assess performance in the
evaluation of plaque length. Agreement between the two
readers was tested using Cohen’s kappa test and was
deemed poor for kappa values of 0.21–0.40, fair for values
of 0.41–0.60, good for values of 0.61–0.80 and excellent
for values of 0.81–1.00 [19]. SNR values were compared
using the Independent-Samples T Test. A p value < 0.05
was considered as statistically significant for all tests used.
Results
MRA and CTA examinations were successfully performed
in all patients, without any adverse reaction related to
gadolinium- or iodine-based contrast agent administra-
tion. 18 carotid arteries were evaluated in the 9 patients in
group A (Gadobutrol-enhanced MRA) and 42 carotid
arteries were evaluated in the 21 patients in group B
(Gadoteridol-enhanced MRA) (Table 1). The average con-
trast agent volume administered was 7.3 ± 1.2 ml [6–10]
in group A and 14 ± 1.9 ml [11–18] in group B.
The quality of MRA examination was deemed excellent
in 4/9 (44.4 %), adequate in 4/9 (44.4 %) and poor in 1/9
(11.1 %) of cases in group A (Gadobutrol-enhanced MRA)
and excellent in 15/21 (71.4 %), adequate in 5/21 (23.8 %)
and poor in 1/21 (4.8 %) of cases in group B (Gadoteridol-
enhanced MRA), without significant differences (Mann–
Whitney test’s p = 0.165). The mean SNR values were
81.09 ± 28.38 [33.03–151.36] in group A and 89.32 ± 70.4
[28.3–277.5] in group B, without significant differences
(independent-Samples T Test p = 0.635) (Fig. 1).
Diagnostic accuracy in the evaluation of vessel stenosis
was 0.94 in group A and 0.93 in group B (sensitivity, spe-
cificity, PPV and NPV are reported in Table 2). ROC curve
analysis (Fig. 2a and b) demonstrated an AUC of 0.974 ±
0.028 [95 % c.i. 0.814–1.0] in group A and 0.969 ± 0.018
[95 % c.i. 0.874–0.999] in group B, without significant
differences in the assessment of vessel stenosis (z-statistic
p = 0.936).
Diagnostic accuracy in the evaluation of plaque morph-
ology was 0.94 in group A and 0.76 in group B (sensitivity,
specificity, PPV and NPV are reported in Table 3).
ROC curve analysis (Fig. 2c and d) demonstrated an
AUC of 0.954 ± 0.045 [95 % c.i. 0.727–0.98] in group
A and 0.813 ± 0.058 [95 % c.i. 0.658–0.913] in group
B, without significant differences in the assessment of
vessel stenosis (z-statistic p = 0.155).
The average plaque length was 12.94 ± 6.23 mm [6–20]
in group A and 11.9 ± 7.4 mm [4–25] in group B.
Pearson’s correlation coefficient revealed a good correl-
ation between MRA and CTA both for Gadoteridol (r =
0.784; p = 0.000) and Gadobutrol (r = 0.751; p = 0.000).
Table 1 Table shows demographic and clinical characteristics
of the groups; categorical data are expressed as number
(percentage), continuous data are described as the mean
value ± Standard Deviation [95 % confidence interval] or
[minimum – maximum] as appropriate
Gadoteridol (n = 21) Gadobutrol (n = 9) p
Sex, male 14 (66.7 %) 5 (55.6 %) 0.57
Age, years 73.38 ± 6.4 [61–85] 68.56 ± 9.3 [51–81] 0.11
Weight, kg 71.29 ± 10.9 [53–92] 71.78 ± 11.4 [57–96] 0.91
Differences between the groups were tested using the unpaired t-test and the
Mann–Whitney according to the nature of examined data
Fig. 1 Figure shows the box plot relative Signal-to-noise ratio according to contrast agents
Zaccagna et al. Neurovascular Imaging  (2015) 1:9 Page 3 of 7
Cohen’s kappa revealed excellent agreement in stenosis
degree evaluation between the two readers (k = 0.861) and
good agreement in morphology detection (k = 0.733) and
length determination (k = 0.722).
Discussion
Very few studies have compared Gadoteridol and Gado-
butrol for clinical applications [20, 21]. In our studyno
significant differences emerge in terms of image quality
and diagnostic accuracy between Gadoteridol-enhanced
and Gadobutrol-enhanced carotid MRA. Several proper-
ties of contrast agents (molecular structure and size,
interaction with blood components, concentration) may
affect R1 relaxivity and thus influence vascular enhance-
ment, image quality and diagnostic performance in
MRA. It has often been claimed that Gadobutrol offers
superior image quality in vascular and extravascular
applications because of its higher gadolinium concen-
tration (1 M) in the marketed vial as compared with
standard contrast agents (0.5 M); however, the clinically
approved dose of Gadobutrol is not different from that
of other extracellular contrast agents (0.1 mmol/kg
bodyweight) and, since it belongs to the extracellular
class of contrast agents, its relaxivity at standard clinical
doses is not affected by the higher concentration [22]. In
line with these observations, our results demonstrate
that Gadoteridol-enhanced carotid MRA is not inferior
to Gadobutrol-enhanced carotid MRA in terms of image
quality and diagnostic accuracy. Moreover, the two
contrast agents were substantially equivalent in the
Table 2 Table shows accuracy, sensibility, specificity, Positive
Predictive Value (PPV) and Negative Predictive Value (NPV) of
Gadoteridol-enhanced MRA and Gadobutrol-enhanced MRA in
determining stenosis degree
Gadoteridol (n = 42) Gadobutrol (n = 18)
Accuracy 0.93 (39/42) 0.94 (17/18)
Sensibility 1 (10/10) 0.86 (6/7)
Specificity 0.91 (29/32) 1 (11/11)
PPV 0.77 (10/13) 1 (6/6)
NPV 1 (29/29) 0.92 (11/12)
Fig. 2 ROC curves for stenosis evaluation (a and b; a for gadoteridol and b for gadobutrol) and plaque morphology (c and d; c for gadoteridol
and d for gadobutrol). Area under the ROC curve is showed for each curves
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evaluation of stenosis degree, plaque morphology and
length (Figs. 3 and 4). As regards the evaluation of image
quality, our results for both subjective assessment and
quantitative measurements of SNR, succeed in demon-
strating the absence of statistically significant differences
in the two groups of patients (p = 0.635). It should be
noted that high field (3T) scanners, as used in our
study, may affect image quality by influencing gadolinium
relaxivity and enhancement generated on T1-weighted
sequences after intravenous injection in a slightly different
manner to that at 1.5T, at which the majority of contrast
agent comparisons have been performed. In particular, at
increasing magnetic field strengths gadolinium R1 relaxivity
tends to decrease, hence one might expect a parallel deteri-
oration of image contrast in MRA; however, the increased
SNR achieved at higher magnetic field, as well as the im-
proved background suppression due to the higher T1 of
extravascular tissues, leads to an overall increase of vascular
enhancement after contrast agent injection [22]. Even if the
relaxivity of both Gadoteridol and Gadobutrol is negatively
affected by the increased field strength, the resulting differ-
ence remains similar to what has been reported at 1.5T,
with a difference that is not sufficient to significantly
influence intravascular enhancement and SNR [6, 23, 24].
The implications of this study for routine practice may
be relevant in terms of cost and convenience, since
Gadoteridol is less expensive (around 80 euros per
single dose vial) in comparison with Gadobutrol (around
130 euros per single dose vial). Moreover Gadoteridol is
the sole agent approved for high-dose administration
(0.3 mmol/kg), due in part to its high stability and lower
potential for toxicity from long-term heavy metal
Table 3 Table shows accuracy, sensibility, specificity, Positive
Predictive Value (PPV) and Negative Predictive Value (NPV) of
Gadoteridol-enhanced MRA and Gadobutrol-enhanced MRA in
plaque morphology evaluation
Gadoteridol (n = 42) Gadobutrol (n = 18)
Accuracy 0.76 (22/42) 0.94 (17/18)
Sensibility 0.63 (12/19) 0.91 (10/11)
Specificity 0.87 (20/23) 1 (7/7)
PPV 0.8 (12/15) 1 (10/10)
NPV 0.74 (20/27) 0.875 (7/8)
Fig. 3 85-year-old male with tight stenosis of right internal carotid artery (arrow). a and b CE-MRA images acquired after 0.2 ml/kg of Gadoteridol,
c and d CTA images. CE-MRA demonstrates a ulcerated plaque causing 60 % stenosis of right internal carotid artery; CTA confirms the findings of
CE-MRA. Vessel delineation on CE-MRA images was deemed as sharp as on CTA images
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deposition [10, 11]; this may represent an additional ad-
vantage at lower magnetic fields [25]. Furthermore, the
adverse effects of Gadoteridol are reported to be very in-
frequent; it contains a cyclic nonionic chelate and has a
high thermodynamic stability constant (23.8) and a long
dissociation half-life (3 h). It’s inclusion in the group of
agents considered to be at low risk for Nephrogenic Sys-
temic Fibrosis is probably related to these properties [26].
It should be noted that this study has some relevant
limitations, the most important being the small sample
size; however an extended study with a larger patient
population is currently ongoing. In addition, digital sub-
traction angiography was not available for comparison in
our series, since just a minority of patients with clinically
significant stenosis underwent stenting procedures while
the others were treated with endarterectomy without
angiography. However, it should be noted that CTA has
been shown to be a valid alternative to DSA as reference
standard in comparative studies and, in daily clinical
practice, it is currently used as the modality of choice
for carotid imaging [27, 28]. Another relevant limitation
is represented by the inter-individual design of the study;
however, this was due to ethical reasons since patients
with significant disease are referred for treatment rather
than a second contrast-enhanced MRA exam. The final
limitation concerns the different sizes of the two patient
groups; however, unequal randomization has been re-
ported to be an accepted strategy in clinical trials to gain
greater experience when comparing a new treatment to a
reference standard, hence we adopted this randomization
due to the lack of data on Gadobutrol-enhanced carotid
MRA (in this regard it is also worth noting that the
statistical power of a 1:1 allocation is 0.95 while the
statistical power of a 2:1 ratio is 0.925, with a negligible
difference).
Conclusions
In conclusion, from our study, similar results of
Gadoteridol-enhanced MRA compared with Gadobutrol-
enhanced MRA were observed, both in terms of image
quality and diagnostic accuracy, in patients undergoing
evaluation of carotid stenosis.
Fig. 4 73-year-old-male referred for carotid imaging to guide revascularization of symptomatic stenosis. a and b CE-MRA images, c and d CTA
images. Images show an atherosclerotic plaque arising from left carotid arteries bifurcation and involving the proximal segment of internal carotid
artery (arrow). Although sagittal-reformatted CE-MRA fails to show residual lumen, axial CE-MRA images demonstrated a severe (90 %) stenosis of
left internal carotid artery; CTA confirmed the severe stenosis as well as the absence of ulceration
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